BioCryst Shares 96-Week Orladeyo Data Highlighting 80% Reduction In HAE Attacks
BioCryst's Orladeyo Application Under Review In Israel For Hereditary Angioedema
KalVista Stock Falls After FDA Institutes Clinical Hold On Hereditary Angioedema Trial With KVD824
Ionis Pharma's Ligand-Conjugated Antisense Hits Primary Endpoint Goal In Hereditary Angioedema Study